Get the Stockscreener App
0.34
2.58%
-0.009
Tscan Therapeutics Inc stock is traded at $0.34, with a volume of 381.05K.
It is down -2.58% in the last 24 hours and down -57.16% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.349
Open:
$0.3521
24h Volume:
381.05K
Relative Volume:
0.45
Market Cap:
$23.04M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.3552
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
+9.01%
1M Performance:
-57.16%
6M Performance:
-67.31%
1Y Performance:
-80.90%
1-Day Range:
$0.33
$0.37
1-Week Range:
$0.3113
$0.3718
52-Week Range:
$0.2902
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.34 | 23.04M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). - Stock Titan
Layoff Tracker: Novo workforce down 13,000 - BioSpace
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from S&P Global BMI Index - marketscreener.com
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - kalkine.com.au
TScan Therapeutics announces retention program for key executives - Investing.com
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com Australia
TScan Therapeutics Launches Executive Retention Incentive Program - TipRanks
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com India
TScan Therapeutics grants retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski - tradingview.com
New milestone-tied pay plan for TScan Therapeutics (TCRX) leaders - Stock Titan
TSCAN THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TARGET PRICE TO $1 FROM $7 - webull.com
H.C. Wainwright Downgrades TScan Therapeutics(TCRX.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com Nigeria
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme StudySlideshow (NASDAQ:TCRX) 2026-09-04 - Seeking Alpha
TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - GuruFocus
Tscan prioritizes in vivo solid tumor program - BioWorld News
TScan Therapeutics IncExpects to Incur Abo - Moomoo
TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Nigeria
Crude Oil Moves Higher; US Factory Orders Rise In July - Benzinga
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Yahoo Finance
TScan Therapeutics Restructures to Focus on Solid Tumors - TipRanks
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - GlobeNewswire
Why is TScan Therapeutics stock collapsing today? - Investing.com
TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation - Bitget
TCRX Q2 2026 Earnings: Wider-than-Expected Loss Weighs on SharesManagement Guidance Update - careplusvn.com
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Barchart.com
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportSeasonality Effect - dars.gov.et
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Yahoo Finance
Is Amgen (AMGN) Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal? - simplywall.st
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
TScan Therapeutics Faces Loss of Key Amgen Partnership - TipRanks
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Up Down Volume - vinanet.vn
Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock - Stock Titan
Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants - Stock Titan
Equities Analysts Set Expectations for TCRX FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - uk.finance.yahoo.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):